Diabetes Therapy Quiz

A 54-year-old woman with a history of Type 2 Diabetes Mellitus (T2DM) presents with a recent weight gain. She is currently on Metformin and a 2nd Generation SU. Which of the following changes in her medication regimen might assist with her weight gain issue?

A 54-year-old woman with a history of Type 2 Diabetes Mellitus (T2DM) presents with a recent weight gain. She is currently on Metformin and a 2nd Generation SU. Which of the following changes in her medication regimen might assist with her weight gain issue?

A 60-year-old man with a history of T2DM, congestive heart failure (CHF), and renal disease is currently taking DPP-4 inhibitors for his diabetes management. Which other medication, when added, might have beneficial effects on both his CHF and renal disease?

A 60-year-old man with a history of T2DM, congestive heart failure (CHF), and renal disease is currently taking DPP-4 inhibitors for his diabetes management. Which other medication, when added, might have beneficial effects on both his CHF and renal disease?

A 65-year-old woman with a history of T2DM presents with frequent hypoglycemic episodes. She is currently on 2nd Generation SU. Which of the following medication switches is likely to reduce her risk of hypoglycemia?

A 65-year-old woman with a history of T2DM presents with frequent hypoglycemic episodes. She is currently on 2nd Generation SU. Which of the following medication switches is likely to reduce her risk of hypoglycemia?

A 45-year-old woman with T2DM has a current HbA1c level of 9.2%. Her diabetes is currently managed with diet and exercise. What can you expect from the addition of a glucose-lowering drug in this patient?

A 45-year-old woman with T2DM has a current HbA1c level of 9.2%. Her diabetes is currently managed with diet and exercise. What can you expect from the addition of a glucose-lowering drug in this patient?

A 60-year-old man with T2DM and significant insulin resistance has a limited response to his current medication, a sulfonylurea. What medication change would likely increase his response?

A 60-year-old man with T2DM and significant insulin resistance has a limited response to his current medication, a sulfonylurea. What medication change would likely increase his response?

A 67-year-old woman with T2DM presents with recurring episodes of hypoglycemia. She is currently on a sulfonylurea with active metabolites. Considering her hypoglycemia episodes, which sulfonylurea might be a better option for her?

A 67-year-old woman with T2DM presents with recurring episodes of hypoglycemia. She is currently on a sulfonylurea with active metabolites. Considering her hypoglycemia episodes, which sulfonylurea might be a better option for her?

A 79-year-old man with T2DM, chronic kidney disease (stage 3), and a recent history of mild hypoglycemic episodes is currently on Glyburide. What adjustment should be considered in his treatment?

A 79-year-old man with T2DM, chronic kidney disease (stage 3), and a recent history of mild hypoglycemic episodes is currently on Glyburide. What adjustment should be considered in his treatment?

A 56-year-old man with newly diagnosed T2DM is prescribed Glimepiride. He does not have any other comorbidities. What should be the recommended starting dose and the progression of his treatment plan?

A 56-year-old man with newly diagnosed T2DM is prescribed Glimepiride. He does not have any other comorbidities. What should be the recommended starting dose and the progression of his treatment plan?

A 58-year-old male with a history of T2DM is brought into the clinic due to repeated episodes of hypoglycemia. His current medications include glyburide. His liver function tests are slightly elevated. Which of the following factors might be contributing to his hypoglycemic episodes?

A 58-year-old male with a history of T2DM is brought into the clinic due to repeated episodes of hypoglycemia. His current medications include glyburide. His liver function tests are slightly elevated. Which of the following factors might be contributing to his hypoglycemic episodes?

You are treating a 72-year-old patient with T2DM who has recently been experiencing a high frequency of severe hypoglycemic episodes. He is currently on glyburide. Considering his age and hypoglycemia risk, what would be the most appropriate action?

You are treating a 72-year-old patient with T2DM who has recently been experiencing a high frequency of severe hypoglycemic episodes. He is currently on glyburide. Considering his age and hypoglycemia risk, what would be the most appropriate action?

A 65-year-old male patient with T2DM has been experiencing secondary failure of sulfonylurea therapy. What is the likely reason for this failure?

A 65-year-old male patient with T2DM has been experiencing secondary failure of sulfonylurea therapy. What is the likely reason for this failure?

A 72-year-old woman with type 2 diabetes has been managed with metformin but her A1c remains suboptimal. She has no known renal or liver disease. You consider adding a sulfonylurea to her regimen. Which of the following sulfonylureas would you prefer to avoid considering her age?

A 72-year-old woman with type 2 diabetes has been managed with metformin but her A1c remains suboptimal. She has no known renal or liver disease. You consider adding a sulfonylurea to her regimen. Which of the following sulfonylureas would you prefer to avoid considering her age?

A 65-year-old male with type 2 diabetes and a known deficiency in glucose 6-phosphate dehydrogenase (G6PD) is being considered for sulfonylurea therapy. What possible side effect should you particularly be cautious about?

A 65-year-old male with type 2 diabetes and a known deficiency in glucose 6-phosphate dehydrogenase (G6PD) is being considered for sulfonylurea therapy. What possible side effect should you particularly be cautious about?

A 52-year-old woman with type 2 diabetes and obesity is being evaluated for her suboptimal glycemic control. She is currently on metformin and lifestyle modifications. You consider adding another antidiabetic agent to her regimen. What would be a potential disadvantage if you choose a sulfonylurea for her?

A 52-year-old woman with type 2 diabetes and obesity is being evaluated for her suboptimal glycemic control. She is currently on metformin and lifestyle modifications. You consider adding another antidiabetic agent to her regimen. What would be a potential disadvantage if you choose a sulfonylurea for her?

A 65-year-old patient with a history of type 2 diabetes, hypertension, and fatty liver disease is currently on metformin therapy. His HbA1c level is 7.8%. His primary issue is postprandial hyperglycemia, while his fasting glucose levels are near normal. Which antidiabetic medication would be the most suitable for this patient?

A 65-year-old patient with a history of type 2 diabetes, hypertension, and fatty liver disease is currently on metformin therapy. His HbA1c level is 7.8%. His primary issue is postprandial hyperglycemia, while his fasting glucose levels are near normal. Which antidiabetic medication would be the most suitable for this patient?

A 48-year-old male, newly diagnosed with type 2 diabetes, has an HbA1c of 9.2%. The patient eats meals at irregular times and has both high fasting and postprandial glucose levels. Which drug would be most suitable for him?

A 48-year-old male, newly diagnosed with type 2 diabetes, has an HbA1c of 9.2%. The patient eats meals at irregular times and has both high fasting and postprandial glucose levels. Which drug would be most suitable for him?

A 60-year-old patient with type 2 diabetes and liver impairment is taking ketoconazole for a fungal infection. He is also on meglitinide therapy. What risk is associated with the combination of meglitinides and ketoconazole?

A 60-year-old patient with type 2 diabetes and liver impairment is taking ketoconazole for a fungal infection. He is also on meglitinide therapy. What risk is associated with the combination of meglitinides and ketoconazole?

A 52-year-old man with a history of type 2 diabetes mellitus comes to the clinic. He is currently on metformin but his fasting glucose levels are not well controlled. He reports taking his metformin twice daily with breakfast and dinner. The doctor decides to increase his dose. Which of the following would be the maximum daily dose of metformin that this patient can be prescribed?

A 52-year-old man with a history of type 2 diabetes mellitus comes to the clinic. He is currently on metformin but his fasting glucose levels are not well controlled. He reports taking his metformin twice daily with breakfast and dinner. The doctor decides to increase his dose. Which of the following would be the maximum daily dose of metformin that this patient can be prescribed?

A 65-year-old woman with type 2 diabetes mellitus is currently on metformin therapy. She is concerned about gaining weight from her medications. Which of the following is the most likely effect of metformin on her body weight?

A 65-year-old woman with type 2 diabetes mellitus is currently on metformin therapy. She is concerned about gaining weight from her medications. Which of the following is the most likely effect of metformin on her body weight?

A 45-year-old man with type 2 diabetes mellitus is concerned about the potential side effects of his medications. He is currently prescribed metformin. What is the most common side effect of metformin?

A 45-year-old man with type 2 diabetes mellitus is concerned about the potential side effects of his medications. He is currently prescribed metformin. What is the most common side effect of metformin?

A 65-year-old woman with a history of Type 2 diabetes managed with metformin comes to the clinic for routine follow-up. She also has a history of chronic kidney disease (eGFR 35mL/min/1.73 m2). She reports experiencing recent worsening of fatigue. What should be the most appropriate next step in her management?

A 65-year-old woman with a history of Type 2 diabetes managed with metformin comes to the clinic for routine follow-up. She also has a history of chronic kidney disease (eGFR 35mL/min/1.73 m2). She reports experiencing recent worsening of fatigue. What should be the most appropriate next step in her management?

A 40-year-old woman with polycystic ovary syndrome (PCOS) and type 2 diabetes has been treated with metformin. She has been feeling fatigued and reports experiencing paresthesias in her hands and feet. Laboratory tests reveal a decrease in B12 levels. What should be the most appropriate next step in her management?

A 40-year-old woman with polycystic ovary syndrome (PCOS) and type 2 diabetes has been treated with metformin. She has been feeling fatigued and reports experiencing paresthesias in her hands and feet. Laboratory tests reveal a decrease in B12 levels. What should be the most appropriate next step in her management?

A 50-year-old man with a history of diabetes, chronic alcoholism, and congestive heart failure is scheduled to undergo an iodinated contrast procedure. His eGFR is 40 mL/min/1.73 m2. He is currently on metformin. What is the most appropriate management of his metformin before the procedure?

A 50-year-old man with a history of diabetes, chronic alcoholism, and congestive heart failure is scheduled to undergo an iodinated contrast procedure. His eGFR is 40 mL/min/1.73 m2. He is currently on metformin. What is the most appropriate management of his metformin before the procedure?

A 55-year-old patient with impaired glucose tolerance and a liver biopsy confirmed diagnosis of NASH is under your treatment. He has recently been randomized to pioglitazone 45 mg/day. What would you expect to observe after six months of therapy?

A 55-year-old patient with impaired glucose tolerance and a liver biopsy confirmed diagnosis of NASH is under your treatment. He has recently been randomized to pioglitazone 45 mg/day. What would you expect to observe after six months of therapy?

A 60-year-old man with T2DM is being treated with a combination of TZDs and insulin. He presents with newly developed edema. What could be the possible reason?

A 60-year-old man with T2DM is being treated with a combination of TZDs and insulin. He presents with newly developed edema. What could be the possible reason?

Which of the following is true regarding the effects of TZDs (Thiazolidinediones) on Congestive Heart Failure (CHF) based on the data from various studies?

Which of the following is true regarding the effects of TZDs (Thiazolidinediones) on Congestive Heart Failure (CHF) based on the data from various studies?

What effect do TZDs have on bone health, particularly in women?

What is the association between pioglitazone use and bladder cancer based on the given data?

A 56-year-old patient with a history of type 2 diabetes mellitus, cardiovascular disease, and nonalcoholic steatohepatitis (NASH) has been prescribed pioglitazone. Which of the following is an advantage of pioglitazone for this patient?

A 45-year-old patient with type 2 diabetes mellitus is being treated with an alpha-glucosidase inhibitor and insulin. In case of hypoglycemia, what should be the immediate treatment?

What is the effect of alpha-glucosidase inhibitors on cardiovascular disease in patients with diabetes?

Which of the following is an advantage of alpha-glucosidase inhibitors like Acarbose?

Which of the following statements is true regarding the effects of SGLT2 inhibitors on glycemic control?

Which of the following statements is true about the cardiovascular effects of SGLT2 inhibitors, according to the EMPA-REG Outcome Trial and the CANVAS Trial?

What is one of the most common side effects of alpha-glucosidase inhibitors like Acarbose?

What is the mechanism of action of SGLT2 inhibitors in the management of diabetes?

A 68-year-old patient with Type 2 Diabetes Mellitus (T2DM), chronic kidney disease, and a history of heart failure is in the clinic for a medication review. Based on the CREDENCE and DECLARE-TIMI 58 Trials, which drug would you consider adding to their regimen?

Which of the following drugs was shown in the DAPA HF trial to be beneficial in patients with pre-existing heart failure, regardless of whether they had diabetes?

Based on the results of the EMPEROR-Reduced and EMPEROR-Preserved Trials, which drug would you consider adding to the regimen of a patient with class II heart failure and an ejection fraction of 40% or less, regardless of their diabetes status?

What effect do TZDs have on bone health, particularly in women?

What is the association between pioglitazone use and bladder cancer based on the given data?

A 56-year-old patient with a history of type 2 diabetes mellitus, cardiovascular disease, and nonalcoholic steatohepatitis (NASH) has been prescribed pioglitazone. Which of the following is an advantage of pioglitazone for this patient?

A 45-year-old patient with type 2 diabetes mellitus is being treated with an alpha-glucosidase inhibitor and insulin. In case of hypoglycemia, what should be the immediate treatment?

What is the effect of alpha-glucosidase inhibitors on cardiovascular disease in patients with diabetes?

Which of the following is an advantage of alpha-glucosidase inhibitors like Acarbose?

Which of the following statements is true regarding the effects of SGLT2 inhibitors on glycemic control?

Which of the following statements is true about the cardiovascular effects of SGLT2 inhibitors, according to the EMPA-REG Outcome Trial and the CANVAS Trial?

What is one of the most common side effects of alpha-glucosidase inhibitors like Acarbose?

What is the mechanism of action of SGLT2 inhibitors in the management of diabetes?

A 68-year-old patient with Type 2 Diabetes Mellitus (T2DM), chronic kidney disease, and a history of heart failure is in the clinic for a medication review. Based on the CREDENCE and DECLARE-TIMI 58 Trials, which drug would you consider adding to their regimen?

Which of the following drugs was shown in the DAPA HF trial to be beneficial in patients with pre-existing heart failure, regardless of whether they had diabetes?

Based on the results of the EMPEROR-Reduced and EMPEROR-Preserved Trials, which drug would you consider adding to the regimen of a patient with class II heart failure and an ejection fraction of 40% or less, regardless of their diabetes status?